

17 January 2017

Anteo Diagnostics meets Vendor Finance commitment related to DIAsource Acquisition

The directors of Anteo Diagnostics Limited (ASX:ADO) are pleased to confirm to the market that Anteo's Vendor Finance commitment related to the purchase of DIAsource due on the 11th January 2017 has been met.

"We continue to be very satisfied with the performance of DIAsource and look forward to providing an update on the 2016 financial performance of DIAsource in the near future" said Mr. Peter Harding-Smith, Anteo Group CFO.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com